Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kelapher is a topical medical device developed by the Greek pharmaceutical company MEDITRINA for the treatment of skin discolorations (dyschromias). The active ingredient is Lactoferrin LT (Lipid Technology), which is a liposomal formulation of lactoferrin, a multifunctional glycoprotein. Kelapher works primarily by chelating free iron in tissues, which reduces hemosiderin-induced pigmentation commonly associated with hematomas, ecchymoses, and postoperative bruising. Beyond its iron-chelating properties, lactoferrin provides antioxidant, anti-inflammatory, antibacterial, and wound-healing benefits. The product is available as a cream and in ampoule form for local application on lesions caused by vascular procedures, varicose ulcers, scars, burns, and post-laser treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kelapher.